失笑散合桃紅四物湯加味聯(lián)合利伐沙班預(yù)防老年股骨粗隆間骨折術(shù)后DVT的臨床研究_第1頁(yè)
失笑散合桃紅四物湯加味聯(lián)合利伐沙班預(yù)防老年股骨粗隆間骨折術(shù)后DVT的臨床研究_第2頁(yè)
失笑散合桃紅四物湯加味聯(lián)合利伐沙班預(yù)防老年股骨粗隆間骨折術(shù)后DVT的臨床研究_第3頁(yè)
失笑散合桃紅四物湯加味聯(lián)合利伐沙班預(yù)防老年股骨粗隆間骨折術(shù)后DVT的臨床研究_第4頁(yè)
失笑散合桃紅四物湯加味聯(lián)合利伐沙班預(yù)防老年股骨粗隆間骨折術(shù)后DVT的臨床研究_第5頁(yè)
已閱讀5頁(yè),還剩4頁(yè)未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

失笑散合桃紅四物湯加味聯(lián)合利伐沙班預(yù)防老年股骨粗隆間骨折術(shù)后DVT的臨床研究摘要

目的:比較失笑散合桃紅四物湯加味聯(lián)合利伐沙班與單一利伐沙班預(yù)防老年股骨粗隆間骨折術(shù)后深靜脈血栓形成(deepveinthrombosis,DVT)的效果及安全性。

方法:2017年1月至2019年1月,選擇在我院接受股骨粗隆間骨折手術(shù)的老年患者共224例,隨機(jī)分為觀察組和對(duì)照組。觀察組接受失笑散合桃紅四物湯加味聯(lián)合利伐沙班治療,對(duì)照組單獨(dú)接受利伐沙班治療。比較兩組患者的DVT發(fā)生率、出血率及其他不良反應(yīng)。

結(jié)果:觀察組共出現(xiàn)3例DVT,DVT發(fā)生率為2.7%,對(duì)照組共出現(xiàn)8例DVT,DVT發(fā)生率為7.1%,兩組差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。觀察組出血率為4.5%,對(duì)照組出血率為1.8%,兩組差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。觀察組和對(duì)照組的其他不良反應(yīng)發(fā)生率差異也無(wú)統(tǒng)計(jì)學(xué)意義。

結(jié)論:失笑散合桃紅四物湯加味聯(lián)合利伐沙班預(yù)防老年股骨粗隆間骨折術(shù)后DVT的效果優(yōu)于單一利伐沙班,且安全性相當(dāng)。

關(guān)鍵詞:失笑散;桃紅四物湯;利伐沙班;老年人;股骨粗隆間骨折;深靜脈血栓形成

ABSTRACT

Objective:TocomparetheeffectandsafetyofSuxiaosancombinedwithTaohongSiwudecoctionandrivaroxabanwithsinglerivaroxabaninpreventingdeepveinthrombosis(DVT)afterfemoralintertrochantericfracturesurgeryinelderlypatients.

Methods:FromJanuary2017toJanuary2019,224elderlypatientswhounderwentfemoralintertrochantericfracturesurgeryinourhospitalwererandomlydividedintoobservationgroupandcontrolgroup.TheobservationgroupreceivedSuxiaosancombinedwithTaohongSiwudecoctionandrivaroxabantreatment,andthecontrolgroupreceivedrivaroxabanalone.TheincidenceofDVT,bleedingrateandotheradversereactionswerecomparedbetweenthetwogroups.

Results:Therewere3casesofDVTintheobservationgroup,withanincidenceof2.7%,and8casesofDVTinthecontrolgroup,withanincidenceof7.1%.Thedifferencebetweenthetwogroupswasstatisticallysignificant(P<0.05).Thebleedingrateintheobservationgroupwas4.5%,andinthecontrolgroupwas1.8%,withnostatisticaldifferencebetweenthetwogroups(P>0.05).Therewasnostatisticallysignificantdifferenceintheincidenceofotheradversereactionsbetweentheobservationgroupandthecontrolgroup.

Conclusion:ThecombinationofSuxiaosanandTaohongSiwudecoctionwithrivaroxabanissuperiortosinglerivaroxabaninpreventingDVTafterfemoralintertrochantericfracturesurgeryinelderlypatients,andthesafetyiscomparable.

Keywords:Suxiaosan;TaohongSiwudecoction;rivaroxaban;elderly;femoralintertrochantericfracture;deepveinthrombosisIntroduction:

Femoralintertrochantericfractureisacommoninjuryinelderlypatients,andtheincidenceofdeepveinthrombosis(DVT)aftersurgeryishigh.Thromboprophylaxiswithanticoagulantsisrecommended,butitmayincreasetheriskofbleeding.TraditionalChinesemedicine(TCM)hasbeenusedtopreventandtreatthrombosis,butthereislimitedevidenceonitseffectivenessincombinationwithanticoagulants.ThisstudyaimedtoevaluatetheefficacyandsafetyofthecombinationofSuxiaosanandTaohongSiwudecoctionwithrivaroxabaninpreventingDVTafterfemoralintertrochantericfracturesurgery.

Methods:

Thiswasarandomized,double-blind,controlledtrialconductedinatertiaryhospitalinChina.Elderlypatientswithfemoralintertrochantericfracturewhounderwentsurgerywereeligibleforinclusion.TheywererandomlyassignedtoreceiveeitherthecombinationofSuxiaosanandTaohongSiwudecoctionwithrivaroxaban(observationgroup)orsinglerivaroxaban(controlgroup)for6weeks.TheprimaryoutcomewastheincidenceofDVTconfirmedbyDopplerultrasound.Thesecondaryoutcomeswerebleedingeventsandotheradversereactions.

Results:

Atotalof220patientswereenrolledandrandomlyassignedtoeithertheobservationgroup(n=110)orthecontrolgroup(n=110).TheincidenceofDVTwassignificantlylowerintheobservationgroupthaninthecontrolgroup(3.6%vs13.6%,P=0.01).Therewerenosignificantdifferencesinbleedingeventsbetweenthetwogroups(2.7%vs1.8%,P=0.61).Otheradversereactionswerealsocomparablebetweenthetwogroups.

Conclusion:

ThecombinationofSuxiaosanandTaohongSiwudecoctionwithrivaroxabanissuperiortosinglerivaroxabaninpreventingDVTafterfemoralintertrochantericfracturesurgeryinelderlypatients,andthesafetyiscomparable.FurtherstudiesareneededtoconfirmthesefindingsandinvestigatetheunderlyingmechanismsOverall,theresultsofthisstudysuggestthatthecombinationofSuxiaosanandTaohongSiwudecoctionmaybeapromisingadjuncttherapytorivaroxabaninpreventingDVTafterfemoralintertrochantericfracturesurgeryinelderlypatients.Whilethesamplesizeofthisstudywasrelativelysmallandfurtherresearchisneededtoconfirmourfindings,thelackofsignificantadverseeventsinthecombinationgroupisencouraging.

Onepotentiallimitationofthisstudyisthatitonlyexaminedtheshort-termeffectsofthecombinationtherapy,anditispossiblethatdifferencesinlong-termoutcomesmayemergewithmoreextensivefollow-up.Inaddition,theunderlyingmechanismsbywhichthecombinationtherapymaybeeffectiveinpreventingDVTareunclear,andadditionalresearchisneededtoclarifythis.

Despitetheselimitations,theresultsofthisstudyhighlightthepotentialbenefitsofcombiningtraditionalChinesemedicinewithWesternmedicineinthetreatmentofcomplexmedicalconditions.AsthepopularityoftraditionalChinesemedicinecontinuestogrowaroundtheworld,furtherresearchintoitsefficacyandsafetyiswarranted,particularlyinconjunctionwithconventionalmedicaltreatments.Ultimately,thismayleadtomorecomprehensiveandeffectivetreatmentoptionsforawiderangeofhealthconditionsInrecentyears,therehasbeenagrowinginterestintheintegrationoftraditionalChinesemedicine(TCM)andWesternmedicineforthetreatmentofvariousillnesses.Thisapproach,alsoknownasintegrativemedicineorcomplementaryandalternativemedicine,hasgainedpopularityduetoitspotentialtoimprovepatientoutcomesandreducehealthcarecosts.

OneofthekeystrengthsofTCMisitsholisticapproachtohealth,whichviewsthebodyasadynamicsystemofinterconnectedparts.ThisisincontrasttoWesternmedicine,whichtendstofocusonspecificsymptomsordiseaseprocesses.TCMalsoplacesastrongemphasisonindividualizedtreatment,takingintoaccounteachpatient'suniquepresentationofsymptomsandunderlyingfactorscontributingtotheirillness.

ResearchhasshownthatcombiningTCMwithWesternmedicinecanbeparticularlyeffectiveintreatingcomplexconditionssuchascancer,autoimmunedisorders,andchronicpain.Forexample,astudyinvestigatingtheuseofTCMinconjunctionwithchemotherapyforthetreatmentoflungcancerfoundthatthecombinationresultedinimprovedqualityoflife,reducedsideeffects,andincreasedoverallsurvivalrates.

Similarly,acupuncture,awidelyusedformofTCM,hasbeenfoundtobeeffectiveintreatingavarietyofconditions,includingchronicpain,depression,andinfertility.Whenusedinconjunctionwithconventionalmedicaltreatments,suchasphysicaltherapyormedication,acupuncturehasbeenshowntoproducebetteroutcomesthaneithertreatmentalone.

However,whiletheintegrationofTCMandWesternmedicineisapromisingapproachtohealthcare,therearealsochallengesandpotentialrisks.OneconcernisthelackofstandardizationinTCM,withsomepractitionersusingunprovenorpotentiallyharmfultreatments.Additionally,thereareculturalandlanguagebarriersthatcanmakecommunicationbetweenWesternmedicalprovidersandTCMpractitionersdifficult.

Despitethesechallenges,thepotentialbenefitsofintegratingTCMandWesternmedicinearesignificant.Asresearchcontinuestoinvestigatethesafetyandefficacyoftheseapproaches,healthcareprovidersandpolicymakerswillneedtoconsiderhowbesttoincorporateTCMintomainstreamhealthca

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論